H.R. 679 (119th)Legislative Design
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Health|AbortionDrug safety, medical device, and laboratory regulation
Current stageCommittee
Referred to the House Committee on Energy and Commerce.
Introduced
Committee
Floor
President
Law
Legislative design
How complete and executable the bill text feels.
iThis page explains why each dimension scored the way it did, and which parts of implementation are explicit versus left to future interpretation.
No legislative design analysis yet for this bill.